For Research Use Only "cDNA display" allows to construct peptides for various targets

De Novo Peptide Discovery Service by Constructing Peptide Library

MeSCue-Janusys Inc. is aiming to support a person's capability of being cured or healed, by satisfying unmet medical needs and inventing drug discovery seeds that will contribute to reduce a medical care costs. One of the most expensive pharmaceutical agents are antibody drugs. To provide safe, efficient, and affordable medical seeds, we are focusing on replacing antibody drug in peptide drugs.
Our proprietary technology, the cDNA display method, will be able to construct peptide libraries that are consisted of unknown or not drug candidates. Moreover, this technique can be used in various applications, includes developing the target peptide into low molecular compounds.

Features

Construct peptide libraries using cDNA display method.
→ Achieve 1 -10¹³ kinds of enormous diversity.
Superior technique that possesses various features for peptide library construction.
→ Enhanced safety and improved target specificity by utilizing circular peptide library.
Application for acquire peptide against cell surface target molecules.
→ Feature of cDNA display technique (high stability) make it possible to select cell surface target molecules.

Fig.1 Schematic procedure for peptide acquisition by cDNA display technique.

Fig. 2 Image for convergence of target molecule binding peptide

Capabilities of peptide lead optimization

Pharmacological activity

- Cyclic peptides effective at inhibiting protein-protein interactions
- Antagonist/agonist activity

Cell surface/intracellular targets

- Identification of peptides targeting cell surface (like GPCR)
- Identification of peptides with membrane permeability property

Therapeutic properties optimization

- in silico molecular simulation of target-peptide interaction
- Target binding peptides designed to mimic small molecule drugs
- Post-screening integration of non-natural amino acids

Advantage of cDNA display method

Feature of cDNA display method

Strong mRNA-peptide linkage through puromycin (Fig.3)
Solid phase with biotin, easy purification step
Improved stability by utilizing cDNA as nucleic acid portion

These superior characteristics allow constructing peptide library that cannot be achieved by other techniques.

Peptide library that has enormous diversity (1 -10¹³ kinds) could be stably constructed.
Various types of peptide library can be constructed, includes small circular to scaffold type.
Ability to screen for the various potential drug target, including cell surface receptors.

⇒ Acquire diverse lead peptide for drug discovery more reliably

Strengths of our patented puromycin linker

Fig.3 Technical details for puromycin linker

Feature

Strong covalent binding between mRNA and peptide through puromycin.
Solid phase can be made with biotinylated linker. This makes it easy to perform purification and reverse transcription, and is possible to produce non-canonical amino acid by post-translational chemical/enzymatic modification, and introduction of crosslinkage.
The linker harboring a primer for reverse transcription, enabling rapid synthesis of cDNA

Coordinate molecule: Puromycin (Antibiotic derived from Actinomyces)
Structure of puromycin linker

This product is "Research reagent". It is prohibited to use against humans or animals in medical care, clinical diagnoses, or as food.